Back to Browse Journals » Vascular Health and Risk Management » Volume 7

Differential clinical profile of candesartan compared to other angiotensin receptor blockers

Authors Cernes R, Mashavi M, Zimlichman R

Published Date December 2011 Volume 2011:7 Pages 749—759

DOI http://dx.doi.org/10.2147/VHRM.S22591

Published 12 December 2011

Relu Cernes1,2, Margarita Mashavi1,3, Reuven Zimlichman1,3
1The Brunner Institute for Cardiovascular Research, Wolfson Medical Center and Tel Aviv University, Tel Aviv, Israel; 2Department of Nephrology, Wolfson Medical Center, Holon, Israel; 3Department of Medicine, Wolfson Medical Center, Holon, Israel

Abstract: The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8–32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article.

Keywords: angiotensin receptor blockers, candesartan, candesartan cilexetil, clinical trials, efficacy studies, safety, blood pressure

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Perindopril for improving cardiovascular events

DiNicolantonio JJ, O’Keefe JH

Vascular Health and Risk Management 2014, 10:539-548

Published Date: 30 August 2014

Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension

Litvin AY, Sukmarova ZN, Elfimova EM, Aksenova AV, Galitsin PV, Rogoza AN, Chazova IE

Vascular Health and Risk Management 2013, 9:229-235

Published Date: 10 May 2013

Differential pharmacology and benefit/risk of azilsartan compared to other sartans

Kurtz TW, Kajiya T

Vascular Health and Risk Management 2012, 8:133-143

Published Date: 28 February 2012

Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program

Abraham I, MacDonald K, Hermans C, Aerts A, Lee C, Brié H, Vancayzeele S

Vascular Health and Risk Management 2011, 7:209-235

Published Date: 31 March 2011

Association between depression and development of coronary artery disease: pathophysiologic and diagnostic implications

Carlos V Serrano Jr, Karina Tiemi Setani, Erica Sakamoto, et al

Vascular Health and Risk Management 2011, 7:159-164

Published Date: 16 March 2011